UPDATE: Morgan Stanley Upgrades Colgate-Palmolive to Overweight, Lowers Price Target to $72 As Firm Notes 'short term, we see underlying organic sales growth trends as improving with the Coronavirus situation given their defensive category exposure and increased cocooning at home.'